



David Palchak MD
Erick Hjortsvang MD
Kimen Colgan PA
Phone: 805.474.9143
Fax: 805.474.9569
office@pcroncology.com

Daratumumab

Daratumumab is a humanized IgG-kappa monoclonal antibody that binds CD38, a molecule commonly found on the malignant cells of multiple myeloma. It is an immunotherapy that is helped to transform myeloma into a chronic disease that most people can live with for many years.

Daratumumab is given by IV infusion. If tolerated then some people can convert to a rapid subcutaneous injection. It is generally given weekly for a time, then tapered to intervals of once every 2-8 weeks depending on the clinical circumstance.

Like other monoclonal antibodies, daratumumab is usually well-tolerated. Potential side effects include:

- Infusion reactions – these occur in about ¼ of patients while in the office and are managed by our team while you are here.
- Fever
- Muscle aches
- Joint pains
- Infections

In contrast, anemia and nerve damage are less common in patients receiving daratumumab than in patients who do not, probably because of better control of myeloma.

David Palchak MD